TP53 and myelodysplastic syndrome: Among patients with TP53 mutations and excess blasts, the OS in the MDS-E group was worse than that in the MDS-NE group[6(95% CI 2.2–9.8)months vs 12(95% CI 8.9–15.1)months, P=0.022].